- In patients with pT3N0 rectal cancer, adjuvant chemoradiotherapy (CRT) was associated with better outcomes than adjuvant chemotherapy (ACT), but only in lower tumors.
Why this matters
- Tumor location could help guide the choice between adjuvant CRT and ACT.
- pT3N0 patients have a low rate of local recurrence after total mesorectal incision, leading to questions as to whether additional radiotherapy would be of benefit.
- Retrospective analysis of 265 patients (115 undergoing adjuvant CRT [median follow-up, 56.4 months]; 150 receiving ACT [median follow-up, 57.1 months]) at Affiliated Cancer Hospital & Institute of Guangzhou Medical University.
- Funding: None.
- Among patients with lower tumors, adjuvant CRT was associated with:
- Longer DFS than ACT: 87.43% vs 70.56% (P=.015), but not OS.
- Lower rate of distant metastasis (5 years: 8.6% vs 22.2%; P=.033).
- Among patients with upper tumor, there were no significant differences in outcomes between the 2 treatment groups.
- Retrospective, single-center.